Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in...
| Metric Name | Value | Trend | |
|---|---|---|---|
| Dividend Yield | 2.6% | ||
| P/E Ratio | 17.6x | ||
| Revenue | 40.338 B | ||
| Net Income to Company | 14.028 B |
| NVO | Peers | Sector | |
|---|---|---|---|
Market Cap | 276.4 B | 18.381 B | 68.313 M |
Price % of 52 Week High | 42.3% | 74.9% | 62.3% |
Dividend Yield | 2.6% | 1.1% | 0.0% |
Shareholder Yield | -0.6% | 3.5% | -0.6% |
1 Year Price Total Return | -49.5% | -10.7% | -11.4% |
Beta (5 Year) | 0.25 | 0.50 | 0.64 |
| (presentment in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 25,476 | 34,400 | 40,338 | 9,755 | 11,902 |
| Operating Income | 10,887 | 15,507 | 19,430 | 4,279 | 5,914 |
| Net Profit | 7,994 | 12,394 | 14,028 | 3,253 | 3,921 |
| Diluted EPS | 1.76 | 2.76 | 3.14 | 0.73 | 0.88 |
| EBITDA | 11,679 | 16,369 | 20,373 | 4,495 | 6,150 |
| Balance Sheet | |||||
| Cash & ST Invest. | 3,394 | 4,477 | 3,654 | 4,477 | 3,654 |
| Current Assets | 15,577 | 20,683 | 22,349 | 20,683 | 22,349 |
| Total Assets | 34,734 | 46,578 | 64,701 | 46,578 | 64,701 |
| Current Liabilities | 17,412 | 25,127 | 30,216 | 25,127 | 30,216 |
| Total Liabilities | 22,715 | 30,795 | 44,770 | 30,795 | 44,770 |
| Total Equity | 12,020 | 15,783 | 19,931 | 15,783 | 19,931 |
| Total Debt | 3,712 | 4,000 | 14,278 | 4,000 | 14,278 |
| Cash Flow Statement | |||||
| Cash Flow Operations | 11,358 | 16,130 | 16,803 | 1,415 | 1,709 |
| Cash From Investing | (3,587) | (6,501) | (17,904) | (2,180) | (12,670) |
| Cash From Financing | (7,457) | (9,354) | 1,213 | (1,498) | 5,117 |
| Free Cash Flow | 9,609 | 12,308 | 10,252 | 21 | (528) |